Abstract
Using real-time PCR (LightCycler) and immunohistochemistry, we have analyzed expression of key components of the vitamin D system in basal cell carcinomas (BCCs) and normal human skin (NS). Increased VDR-immunoreactivity was demonstrated in BCCs using a streptavidin-peroxidase technique. RNA expression of vitamin D receptor (VDR) and of main enzymes involved in synthesis and metabolism of calcitriol (vitamin D-25-hydroxylase [25-OHase], 25-hydroxyvitamin D-1α-hydroxylase [1α-OHase], 1,25-dihydroxyvitamin D-24-hydroxylase [24-OHase]) was detected in BCCs and NS. Expression levels were determined as ratios between target genes (VDR, 1α-OHase, 25-OHase, 24-OHase) and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control. Median of mRNA ratios for VDR/GAPDH (BCCs: 16.54; NS: 0.00021), 1α-OHase/GAPDH (BCCs: 0.739; NS 0.000803) and 24-OHase/GAPDH (BCCs: 0.00585; NS 0.000000366) was significantly (Wilcoxon–Mann–Whitney U-test) elevated in BCCs. In contrast, median of mRNA ratio for 25-OHase/GAPDH (BCCs: 0.17; NS: 0.016) was not significantly altered in BCCs as compared to NS. Additionally, we report for the first time expression of 1α-OHase splice variants in BCCs and NS, that were detected using conventional RT-PCR. In conclusion, our findings provide supportive evidence for the concept that endogeneous synthesis and metabolism of vitamin D metabolites as well as VDR expression may regulate growth characteristics of BCCs. New vitamin D analogs that exert little calcemic side effects, their precursors, or inhibitors of 24-OHase may offer a new approach for the prevention or therapy of BCCs. The function of alternative transcripts of 1α-OHase that we describe here for the first time in BCCs and NS and their effect on activity level has to be investigated in future experiments.
Similar content being viewed by others
Main
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3 or calcitriol), the biologically active metabolite of vitamin D, has been shown to regulate the growth of various cell types, including human keratinocytes.1, 2, 3 This potent seco-steroid hormone acts via binding to a corresponding intranuclear receptor (VDR), present in target tissues.4, 5 VDR belongs to the superfamily of trans-acting transcriptional regulatory factors, which includes the steroid and thyroid hormone receptors as well as the retinoid-X receptors and retinoic acid receptors.6, 7, 8 Keratinocytes express VDR,1, 9 whose natural ligand, calcitriol, inhibits proliferation and induces differentiation of cultured human keratinocytes in vitro.1, 3 Transcriptional regulation of cell cycle regulatory proteins including WAF-1, and other proteins involved in keratinocyte growth and differentiation, including β3-integrin and fibronectin, by calcitriol has been shown.10, 11, 12 Clinically, the antiproliferative and prodifferentiating effects of vitamin D analogs are used successfully in the treatment of the hyperproliferative skin disease psoriasis.13, 14, 15 Combination of 1,25-dihydroxyvitamin D3 and isotretinoin was reported to be effective in the chemotherapy of precancerous and cancerous skin lesions, including squamous and basal cell carcinomas (BCC).16 Additionally, it has been shown that VDR ablation sensitizes skin to chemically induced carcinogenesis.17 BCC is the most common malignant tumor of the skin.18, 19 Most theories propose that BCC arise from keratinocyte stem cells in the epidermal basal layer or from adnexal structures, but consensus concerning the origin and differentiation of this tumor is still lacking. BCCs are semimalignant skin tumors characterized by a locally aggressive and invasive growth pattern, but, except for very rare cases, have nonmetastasizing behavior.18 The hedgehog signaling pathway has been identified to be crucial to the development of basal cell carcinomas.20, 21 However, the biological mechanisms underlying the unique characteristics of BCC tumor growth are still completely unknown.22
There are two principal enzymes involved in the formation of circulating 1α,25(OH)2D3 from vitamin D, the hepatic microsomal or mitochondrial vitamin D-25-hydroxylase (25-OHase) and the renal mitochondrial enzyme 1α-hydroxylase (1α-OHase) for vitamin D and 25(OH)D3, respectively.23, 24 These hydroxylases belong to a class of proteins known as cytochrome P450 mixed function monooxidases. Extrarenal activity of 25(OH)D3-1α-hydroxylase has been reported in various cell types including macrophages, keratinocytes, prostate and colon cancer cells.25, 26, 27, 28, 29
The aim of this study was to analyze the expression of the vitamin D system in BCCs. We addressed the following questions: (i) Do BCCs express the main enzymes involved in the formation or metabolism of calcitriol, indicating that endogenous synthesis or metabolism of vitamin D metabolites may be involved in growth regulation of BCCs? (ii) Are mRNA-levels for VDR, 1α-OHase, 24-OHase or 25-OHase in BCCs different as compared to normal human skin, indicating that vitamin D synthesis and metabolism are altered in BCCs? iii) Are BCCs potential targets for prevention or therapy with new vitamin D analogs that exert little calcemic side effects or by pharmacological modulation of calcitriol synthesis/metabolism?
Materials and methods
Skin Specimens
For immunohistochemistry and RNA analysis, freshly excised cutaneous BCC specimens (n=15; male: n=9, female: n=6; mean age: 60.9 years) and biopsies of normal skin (n=5; male: n=3, female: n=2; mean age 55.6 years; healthy volunteers, no history of skin disease) were immediately separated from surrounding connective and fat tissue, embedded in OCT Tissue-Tek II (Miles Laboratories, Naperville, IL, USA), snap-frozen in liquid nitrogen, and stored at −70 °C.
Immunohistochemistry
Primary antibody directed against VDR
We used the rat monoclonal antibody 9A7γ (IgG2b; MU 193-UC, BioGenex, CA, USA) that is directed against partially purified vitamin D receptor from chicken intestine and cross reacts with human, mouse, and rat VDRs, but does not bind to glucocorticoid or estrogen receptors.30
Preparation of sections and fixation
Serial sections (5 μm) were cut on a cryostat (Frigocut 2800, Reichert-Jung, Heidelberg, Germany) and mounted on pretreated glass slides. Pretreatment of slides with 2% aminopropylmethoxysilane (Sigma, München, Germany) in acetone for 5 min was performed to enhance sticking of sections during the staining procedure. Frozen sections to be stained for VDR were fixed in 3.7% paraformaldehyde (Merck 4005, Darmstadt, Germany) in phosphate-buffered saline (PBS) for 10 min at room temperature (RT), incubated in methanol (Merck 6009, 3 min, −20°C) and acetone (Merck 22, 60 s, −20°C), and transferred into PBS.
In situ detection of vitamin D receptor
Incubation steps were performed in a moist chamber at RT. The slides to be stained for VDR were incubated with the rat monoclonal antibody 9A7γ (16 h, 4°C) at a dilution of 1:500. After intermediate washing steps (PBS/TBS, 2 × 5 min), the sections were incubated with biotin-labeled rabbit anti-rat IgG (DAKO) at a dilution of 1:400 (30 min, RT), and then with streptavidin–peroxidase complexes (DAKO) at a dilution of 1:400 (30 min, RT), streptavidin-Cy3 (Dianova, Hamburg, Germany) or streptavidin-FITC (Dianova, Hamburg, Germany). After rinsing, streptavidin–peroxidase-labeled sections were incubated with 3-amino-9-ethylcarbazole (AEC, SIGMA, München, Germany) as a substrate for the peroxidase reaction, transferred into tap water, and mounted with AquaTex (Merck). Cy3- or FITC-labeled specimens were mounted with glycerin/PBS (1:10) after a final washing step. In control sections, primary antibody was replaced with polyclonal rat IgG or rabbit IgG (DAKO). No immunoreactivity was observed in these control sections. Specimens were analyzed under a Zeiss microscope (Zeiss, Oberkochen, Germany) or by confocal laser scanning microscopy (LSM2, Zeiss) equipped with a helium–neon-laser (543 nm) as described previously.31 Photographs were taken on Kodak Ektachrome 64 or Agfa CTX 100 film.
Conventional RT-PCR for the Analysis of 25-Hydroxyvitamin D-1α-Hydroxylase mRNA
The glioblastoma cell line TX3868 was established and cultured as described previously.32 RNA isolation from the tumor cell line was performed with Trizol (GIBCO BRL, Rockville, MD USA), based on the same principle as TRI REAGENT.33 The RNA was quantified spectrophotometrically, and its integrity was controlled by denaturing agarose gel electrophoresis.
Total RNA was DNaseI treated prior to RT-PCR. The absence of genomic DNA was confirmed by Alu-PCR. First strand cDNA was synthesized with the Omniscript RT kit (QIAgen, Hilden, Germany) using 2 μg of total RNA, oligo d(T)-Primer and Omniscript-Reverse Transcriptase in a volume of 20 μl. In all, 3 μl of the first-strand cDNA template were utilized in the following PCR. The mastermix for the reactions contained 0.5 μl Taq-DNA Polymerase (5 U/μl; GIBCO BRL, USA), 5 μl 10 × RT-buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl], 0.25 μl of 20 mM each dNTP, 1.5 μl MgCl2 (50 mM), 0.25 μM of each primer (GAPDH and Gap; MWG Biotech, Germany) and 38.75 μl of RNAse-free water.
RT-PCR standardization was performed with GAPDH specific primers, 34. The protocol (denaturation 94°C, 60 s; annealing 58°C, 45 s; elongation 72°C, 45 s) consisted of 24 cycles to ensure a linear range of the PCR-reaction. To analyze 1α-OHase splice variants, specific primers termed Gap were chosen from exon 3 and exon 8.34 PCR conditions for this analysis was denaturation 94°C, 60 s; annealing 60°C, 60 s; elongation 72°C, 60 s for 34 cycles.
Real-time RT-PCR for the analysis of VDR mRNA expression in NS and BCC
RNA isolation. RNA from skin samples was isolated using the TRI REAGENT kit (2 ml reagent on 100–200 mg of tissue; SIGMA, Germany) as described in the manufacturer's protocol. The integrity of RNA was electrophoretically verified through agarose gels staining with ethidium bromide and the bands visualized under UV light.
cDNA synthesis. In all, 7 μl of eluted RNA from each sample were preincubated with 0.5 μg of random hexamer primer (Promega, WI, USA) in a 8 μl solution for 5 min at 65°C. After chilling on ice, 5 μl of 5 × RT-buffer [250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2, 50 mM DTT (1,4-Dithiothreitol)], 2.5 μl of 2.5 mM each dNTP, 8 μl of RNAse-free water, 40 units of Rnasin ribonuclease inhibitor (Promega) and 0.5 μl of M-MLV-RT (Moloney Murine Leukemia Virus Reverse Transcriptase; 200 units/μl; Promega) were added to a final volume of 25 μl. The reaction mixture was then incubated for 60 min at 37°C and reverse transcriptase was finally inactivated at 65°C for 10 min. The cDNA samples were stored at 4°C.
Real-time RT-PCR (LightCycler). Expression of target genes (VDR, 1α-OHase, 24-OHase and 25-OHase) was analyzed using a real-time quantification method (LightCycler) according to the manufacturer's recommendations (Roche Diagnostics, Mannheim, Germany). Hybridization probes, used as detection format, consist of two different oligonucleotides. One probe is labeled at the 5′-end with LC-Red 640, the second probe is labeled at the 3′-end with fluorescein. (TIB MOLBIOL, Berlin, Germany). To avoid amplification of contaminating genomic DNA, the two primers were placed in different exons. PCR sequence-specific primers and hybridization probes are shown in Table 1.
As the precise amount of total RNA added to each reaction and its quality are both difficult to determine, the target gene was normalized with an endogenous standard (GAPDH). To quantify the transcripts in this study, the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was served as internal RNA control. Target gene (VDR, 1α-OHase, 24-OHase and 25-OHase) expression of each sample was evaluated on the basis of its GAPDH content. Standard curves were used to determine the concentration of VDR, 1α-OHase, 24-OHase and 25-OHase and GAPDH gene products. Purified PCR products (High Pure PCR Product Purification Kit, Roche Diagnostics) for VDR, 1α-OHase, 24-OHase, 25-OHase and GAPDH (as shown below) were used in different concentrations to create external standard curves. Using this quantification method, 10-fold dilutions of the homologous standards and the target samples for the analysis of VDR, 1α-OHase, 24-OHase, 25-OHase and GAPDH gene expression were prepared in separate glass capillaries and amplified during the same run. DNA concentration of standards was quantified with a spectrophotometer at OD260. Each PCR run consisted of five external standards and a no-template control.
The 20 μl reaction mixture consisted of a mastermix containing Taq DNA polymerase, dNTP mix and reaction buffer (LightCycler-Fast Start DNA Master Hybridization Kit, Roche). MgCl2 was added in different concentrations: for 1α-OHase 2.5 mM MgCl2, for 25-OHase and GAPDH 3 mM MgCl2, for VDR and 24-OHase 4 mM MgCl2. An amount of 0.5 μM of each primer, 0.25 μM of each probe and 2 μl of template cDNA was used in all assays except for the 1α-OHase where 0.15 μM of each probe was applied. Amplification and detection were carried out as follows. After an initial preincubation and denaturation step of 10 min at 95°C, amplification was performed in a three-step cycle procedure (denaturation 95°C, 10 s, ramp rate 20°C/s; annealing 60°C, 10 s, ramp rate 20°C/s; and elongation 72°C, 5 s, ramp rate 20°C/s) for 50 cycles and the final cooling. With the exception of the 1α-OHase the amplification conditions were 95°C, 5 s, ramp rate 20°C/s for denaturation, 55°C, 8 s, ramp rate 20°C/s for annealing and 72°C, 12 s, ramp rate 20°C/s for elongation.
Quantification of target gene expression was obtained by direct comparison with external standards amplified in parallel reactions in the same run. After real-time data acquisition, the parameter Ct (threshold cycle) was calculated by determining the point at which the fluorescence exceeds an arbitrary threshold limit. The threshold limit was manually set to cross the fluorescent signal of all standards in the exponential phase. The target load in unknown samples was quantified by measuring Ct and by using a standard curve to determine the starting target message quantity.
For an accurate quantification of target DNA, the amplification efficiency of the target was the same as for the standard. The slope of the standard curve was converted to amplification efficiency E by the following algorithm: E=10−1/slope. The amplification efficiency of target (VDR, 1α-OHase, 24-OHase and 25-OHase) and housekeeping gene (GAPDH) did not differ more than ±0.05. Finally the target gene/GAPDH ratio was calculated in order to normalize the data.
Statistical Analysis
The nonparametric Wilcoxon–Mann–Whitney U-test was used to evaluate the target gene/GAPDH ratios in skin samples.35
Results
1,25-Dihydroxyvitamin D3 Receptor (VDR) mRNA and Protein Content is Elevated in BCC
Strong VDR immunoreactivity was observed in all BCCs analyzed (n=15) (Figure 1). Almost every tumor cell revealed nuclear immunoreactivity for VDR. There was no visual difference comparing VDR staining pattern in the different variants of BCCs (nodular type, superficial type, fibrosing type). In general, VDR immunoreactivity was pronounced in the palisaded array of peripheral tumor cells. This staining pattern was detected focally in seven specimens and continuously in eight biopsies. VDR staining intensity was markedly stronger in BCCs as compared to adjacent epidermis or to distant unaffected epidermis of the same section (Figure 1, Table 2). No differences in distribution or intensity of VDR staining were detected when comparing adjacent to distant unaffected epidermis. Keratinocytes of all viable epidermal cell layers revealed nuclear immunoreactivity for VDR, that was pronounced in some specimens in lower epidermal cell layers (Figure 1).
Real-time PCR analysis showed a markedly increased ratio of VDR/GAPDH gene expression in BCCs (median: 16.54; ranging from 0 to 114.0) as compared to normal human skin (median: 0.00021; ranging from 0 to 0.00008; P=0.0032) (Figure 2a).
RNA Levels of 1α-OHase, 24-OHase and 25-OHase are Increased in BCC
Real-Time PCR analysis showed ratios of 1α-OHase/GAPDH (Figure 2b; BCCs: median: 0.739; ranging from 0.025 to 53.1; NS: median: 0.000803; ranging from 0.000016 to 0.0114; P=0.0004), and 24-OHase/GAPDH (Figure 2c; BCCs: median: 0.0058; ranging from 0.00005 to 27.2; NS: median: 0.000000366; ranging from 0.00000009 to 0.00005; P=0.0004) gene expression in BCCs that was significantly increased as compared to NS (Figure 2b, 3.4). Ratio of 25-OHase/GAPDH (Figure 2d; BCCs: median: 0.17; ranging from 0 to 3; NS: median: 0.0166; ranging from 0 to 0.00008; P=0.62) was not significantly altered in BCCs as compared to NS.
Detection of 25-Hydroxyvitamin D-1α-Hydroxylase Splice Variants in NS and BCCs
We performed conventional RT-PCR with five samples from BCC and three samples of NS to examine the expression of the 1α-OHase gene in BCC. The glioblastoma cell-line TX3868 showing overexpression of 1α-OHase, due to amplification of the 1α-OHase gene,34 served as a control. RT-PCR standardization was with primers specific for the gene of GAPDH, that is known to be expressed equally (Figure 3a). 1α-OHase specific RT-PCR was performed with primers that bind in exon 3 and 8, allowing in addition the identification of previously reported splice variants.34 RT-PCR analysis showed three signals at 966, 763 and 389 bp (Figure 3b). The signals demonstrate for the first time in NS and BCC, splice variants of the 1α-OHase gene named Hyd-V1–Hyd-V5 as we have reported before in glioblastomas and in a glioblastoma cell line.34 The fragment of 389 bp can be produced by Hyd-V1 and Hyd-V2 lacking exons 4 and 5 whereas the product of 763 bp can be generated by Hyd-V4 or the normal cDNA of the 1α-OHase gene. The 966 bp product can be assigned to the Hyd-V5 variant containing intron 5. Hyd-V3 could not be amplified with the primers used in this study due to the deletion of the binding site of the reverse primer in the beginning of exon 8. The glioblastoma cell line, TX3868 revealed the strongest expression of normal 1α-OHase-RNA and all splicing variants, when compared to BCCs or NS. In three samples of normal skin, the expression profile of the 1α-OHase and splicing variants was weaker in quantity, but comparable in quality to the glioblastoma cell line. In contrast, no expression of 1α-OHase was detected in three out of five BCCs using conventional RT-PCR as described in Materials and methods. One BCC showed strong expression of the signal corresponding to the normal enzyme and weak signals of all splicing variants, while another BCC revealed the signals corresponding to the normal enzyme and Hyd-V4 by 763 bp. However, because of the weak signal of 763 bp, the overall intensity in this sample might be too weak to detect all splicing variants. Summarizing our results with conventional PCR, we report for the first time splicing variants of 1α-OHase in NS and BCCs. These splice variants were previously described in glioblastoma.
Discussion
The monoclonal antibody 9A7γ has been used successfully in the immunohistochemical investigation of VDR in various tissues such as chicken intestine, rat brain, disaggregated rat bone cells, rat osteosarcoma 17/2.8 cells fibroblasts, normal and psoriatic human skin.9, 31, 36, 37, 38, 39, 40 We have characterized the immunohistochemical staining pattern of MoAb 9A7γ in BCCs.41 All BCC samples analyzed in this study revealed strong VDR-immunoreactivity that was comparable to results that we have published previously.41 Additionally, VDR mRNA expression was analyzed using real-time PCR. VDR immunoreactivity and mRNA content was much stronger in tumor tissue as compared to NS, indicating increased levels of VDR protein and mRNA in these tumor cells. It appears that cellular VDR expression may be a function of the state of differentiation. In various cell cultures, including human keratinocytes, VDR displays highest maximal ligand binding in the early logarithmic phase of cell growth and diminishes as cells reach confluence.42 Our observation of increased VDR expression in BCCs could reflect the altered differentiation pattern in these tumor cells. However, we did not find differences comparing VDR immunoreactivity or VDR mRNA content in different types of BCCs (nodular type, superficial type, fibrosing type). These results are in accordance with results that we have published previously.41
Regulation of proliferation and differentiation in various cell types, including keratinocytes, has been demonstrated by 1,25-dihydroxyvitamin D3 and its corresponding receptor.3 Vitamin D response elements are beginning to be identified in genes involved in cellular growth, differentiation, apoptosis, invasion and metastasis of tumor cells; that is, cell cycle regulators such as the human p21/WAF1, cyclin A and cyclin E genes, the human nm23.H1 gene, the human c-fms, c-fos, c-jun, and c-myc genes, the human retinoblastoma gene, the murine fibronectin gene, the human plasminogen activator inhibitor 2 gene, the human laminin and laminin receptor (α6) genes, and the chicken β3-integrin gene.7, 43, 44 Therefore, we conclude that modulation of VDR expression may be of importance for the unique growth characteristics of BCCs.
It has been demonstrated that VDR require heterodimerization with auxiliary proteins for effective DNA interaction.45, 46 These auxiliary proteins have been identified as the retinoid-X receptors (RXR)-α, -β, and -γ.8, 45, 46 Heterodimerization of VDR with auxiliary proteins has been shown to increase the transcriptional function and DNA binding to the respective response elements in target genes.8, 45, 46 Different classes of vitamin D response elements have been identified that are activated either by VDR-homodimers or by heterodimers of VDR and RXRs or retinoic acid receptors (RAR).7 It was demonstrated that ligands for RXRs and RARs can enhance the transcriptional activity of 1,25-D3 mediated nuclear signaling pathways.7 We have shown expression of RXR and RAR-isotypes in BCCs previously.47 Therefore, we conclude that different vitamin D signaling pathways are present in BCCs that are determined by the RXR- or RAR- ligand and the nature of the response element.
Using real-time PCR analysis, we show significantly increased mRNA levels of the main enzymes involved in the synthesis and metabolism of calcitriol in these tumors. It can be speculated whether the increased content of VDR on the mRNA and protein levels that we have shown is due to an increased formation of calcitriol in BCCs. In contrast to over-expression of 24-OHase that abrogates calcitriol-mediated growth control, overexpression of functionally intact 25-OHase and 1α-OHase results in an increased synthesis of biologically active vitamin D (calcitriol) and should thereby exert antiproliferative and prodifferentiating effects. In various cell types, calcitriol has been shown to enhance VDR expression at the mRNA and protein levels in vitro.48, 49 Interestingly, this elevation of the VDR protein following calcitriol administration is due to an increased transcription of the VDR gene and/or an increased receptor protein lifetime.49 It has been shown that human keratinocytes have the capacity to hydroxylate vitamin D at the C-1 and C-25 positions.50, 51 Therefore, keratinocytes are able not only to produce vitamin D by the action of UV light, but also to synthesize the biologically active vitamin D metabolite, 1,25(OH)2D3. After the time of the initial submission of this manuscript, we have reported additional findings documenting the critical importance of the vitamin D biosynthetic system in the pathogenesis of various cutaneous malignancies including squamous cell carcinomas and supporting the importance of the vitamin D system in BCCs.52
We and others have shown that cytokines and other factors that stimulate transmembrane-signaling pathways alter VDR levels in keratinocytes and other cell types in vitro.53, 54 Surrounding stroma of BCCs often contains an increased number of inflammatory cells. Excreted cytokines and inflammatory peptides of these cells may be a reason for increased VDR expression in adjacent tumor cells.
Investigations in numerous cancer cell lines have shown that high concentrations of calcitriol (10−9–10−7 M) inhibit the growth of tumor cells in vitro. Additionally, it has been demonstrated that calcitriol has beneficial effects in various in vivo models of different types of cancer (reviewed in Hansen et al,43 and Reichrath.44 Therefore, if the overexpression of 1α-OHase results in an overproduction of biologically active calcitriol, the accumulation of this metabolite should inhibit growth and invasion of BCCs. It can be speculated whether overexpression of 25-OHase and 1α-OHase in BCCs represents a physiological feedback loop coupled to the increased proliferative activity in these tumors. However, one has to keep in mind that calcitriol may be rapidly metabolized via 24-OHase, that we show is overexpressed in BCCs as well. In conclusion, it is not known whether overexpression of 25-OHase, 1α-OHase and 24-OHase genes results in increased or reduced levels of calcitriol in BCCs. In this context, the function of alternative transcripts of 1α-OHase and their effect on activity level has to be investigated in future experiments. Additionally, the question of cellular or systemic consequences of the endogenous overexpression of 1α-OHase and 24-OHase in BCC remains to be clarified.
Using array CGH, amplification of 24-OHase was detected as a likely target oncogene of the amplification unit 20q13.2 in breast cancer cell lines and tumors.55 It has been speculated that overexpression of 24-OHase due to gene amplification may abrogate vitamin D3-mediated growth control. We have detected overexpression of 24-OHase mRNA in cutaneous BCCs that may be of importance for the growth characteristics and metastatic behavior of these tumors. It is not known whether overexpression of the 24-OHase gene in BCCs is a result of gene amplification or different mechanisms such as transcriptional regulation. It can be speculated whether pharmacological inhibition of 24-OHase activity in BCCs may be effective in the treatment of these tumors, increasing their sensitivity to the antiproliferative effects of endogeneous or therapeutically applied vitamin D analogs.
Overexpression of 1α-OHase and 25-OHase genes in BCCs suggests that precursors of biologically active calcitriol may be used for the treatment of BCCs. A great deal of work has been done evaluating the chemotherapeutic and/or chemopreventive effects of retinoids on BCCs. The steroid hormone responsiveness is directly proportional to the number of corresponding receptors.48 As VDR mediates the biological effects of calcitriol and analogs on proliferation and differentiation in target cells, increased VDR content in cutaneous BCCs may indicate a high sensitivity to endogeneous or therapeutically applied calcitriol. Combination of 1,25-dihydroxyvitamin D3 and retinoids was reported to be effective in the treatment of precancerous and cancerous skin lesions, including actinic keratoses, squamous cell carcinomas, cutaneous T-cell lymphomas, and BCCs.16 The results reported herein are encouraging; however, much more work is required to establish a role for endogeneously produced or therapeutically applied vitamin D analogs in the chemoprevention of these tumors.
References
Smith EL, Walworth NC, Holick MF . Effect of 1α,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal cells. J Invest Dermatol 1986;86:709–714.
Bikle DD, Pillai S . Vitamin D, calcium and epidermal differentiation. Endocr Rev 1993;14:3–19.
Gniadecki R . Stimulation versus inhibition of keratinocyte growth by 1,25-dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996;294:510–516.
Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary and parathyroid. Science 1979;209:1189–1190.
Baker AR, McDonnell DP, Hughes M . Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988;85:3294–3298.
Evans RM . The steroid and thyroid hormone receptor superfamily. Science 1988;240:889–895.
Haussler MR, Mangelsdorf DJ, Komm BS, et al. Molecular biology of vitamin D hormone. Recent Prog Horm Res 1988;44:263–305.
Kliewer SA, Umesono K, Mangelsdorf DJ, et al. Retinoic X receptor interacts with nuclear receptors in retinoic acid, thyreoid hormone and vitamin D3 signalling. Nature 1992;355:446–449.
Milde P, Hauser U, Simon T, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991;97:230–239.
Cao X, Ross FP, Zhang L, et al. Cloning of the promoter for the avian integrin ß3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3 . J Biol Chem 1993;268:27371–27380.
Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142–153.
Polly P, Carlberg C, Eisman JA, et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by vitamin D3 receptor homodimers. J Cell Biochem 1996;60:322–333.
Kragballe K . Vitamin D analogues in the treatment of psoriasis. J Cell Biochem 1992;49:46–52.
Perez A, Chen TC, Turner A, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:238–246.
Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070–1078.
Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 1994;344:1510–1511.
Zinser GM, Sundberg JP, Welsh J . Vitamin D3receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 2002;23:2103–2109.
Miller SJ . Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 1991;24:1–13.
Miller SJ . Biology of basal cell carcinoma (Part II). J Am Acad Dermatol 1991;24:161–175.
Bale AE, Yu KP . The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001;10:757–762.
Lacour JP . Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 2002;146:17–19.
Ramachandran S, Fryer AA, Smith AG, et al. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 2001;11:247–254.
Nebert DW, Gonzalez FJ . P450 genes: structure, evolution, and regulation. Ann Rev Biochem 1987;56:945–993.
Henry HL . Vitamin D hydroxylase. J Cell Biochem 1992;49:4–9.
Bikle DD, Nemanic MF, Gee E, et al. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest 1986;78:557–566.
Mawer EB, Hayes ME, Heys SE, et al. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. J Clin Endocrinol Metab 1994;79:554–560.
Cross HS, Peterlik M, Reddy S, et al. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1α-hydroxylase activity and regulation of side chain metabolism. J Steroid Biochem Mol Biol 1997;62:21–28.
Jones G, Ramshaw H, Zhang A, et al. Expression and activity of vitamin D-metabolizing cytochrome P450 s (CYP1α and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 1999;140:3303–3310.
Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001;26;357:1673–1674.
Pike JW, Donaldson CA, Marion SL, et al. Development of hybridomas secreting monoclonal antibodies to the chicken intestinal 1α,25-dihydroxyvitamin D3 receptor. Proc Natl Acad Sci USA 1982;79:7719–7723.
Reichrath J, Classen UG, Meineke V, et al. Immunoreactivity of six monoclonal antibodies directed against 1,25-dihydroxyvitamin D3 receptors in human skin. Histochem J 2000;32:625–629.
Fischer U, Gracia U, Elkahloun A, et al. Isolation of genes amplified in human cancers by microdissection mediated cDNA capture. Hum Mol Genet 1996;5:595–600.
Chomczynski P . A reagent for the single-step simultaneous isolation of RNA, DNA and protein from cell and tissue samples. BioTechniques 1993;15:532–534.
Maas RM, Reus K, Diesel B, et al. Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D3-1,alpha-hydroxylase (CYP 27B1) in human malignant glioma. Clin Cancer Res 2001;7:868–875.
Sachs L . Der Vergleich zweier unabhängiger Stichproben: U-Test nach Wilcoxon, Mann und Whitney. In: Sachs L (ed.) Angewandte Statistik, Springer: Berlin, Heidelberg, New York, Tokyo, 1997, pp 230–237.
Berger U, Wilson P, McClelland RA . Immunohistochemical detection of 1,25-dihydroxyvitamin D3 receptors in normal human tissues. J Clin Endocrinol Metab 1988;67:607–613.
Clemens TL, Garrett KP, Zhou XY, et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 1988;122:1224–1230.
Barsony J, Pike JW, DeLuca HF, et al. Immunocytology with microwave-fixed fibroblasts shows 1α,25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. J Cell Biol 1990;111:2385–2395.
Reichrath J, Collins ED, Epple S, et al. Immunohistochemical detection of 1,25-dihydroxyvitamin D3 receptors (VDR) in human skin: a comparison of five antibodies. Pathol Res Pract 1996;192:281–289.
Reichrath J, Müller SM, Kerber A, et al. Biologic effects of topical calcipotriol (MC903) treatment in psoriatic skin. J Am Acad Dermatol 1997;36:19–28.
Reichrath J, Kamradt J, Zhu XH, et al. Analysis of 1,25-dihydroxyvitamin D3 receptors (VDR) in basal cell carcinomas. Am J Pathol 1999;155:583–589.
Mangelsdorf DJ, Pike J, Haussler MR . Avian and mammalian receptors for 1,25-dihydroxyvitamin D3: in vitro translation to characterize size and hormone-dependent regulation. Proc Natl Acad Sci USA 1987;84:354–358.
Hansen CM, Binderup L, Hamberg KJ, et al. Vitamin D and Cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 2001;6:820–848.
Reichrath J . Will analogs of 1,25-dihydroxyvitamin D3 (calcitriol) open a new era in cancer therapy? Onkologie 2001;24:128–133.
Yu VC, Deisert C, Andersen B . RXRß: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 1991;67:1251–1266.
Leid M, Kastner P, Lyons R . Purification, cloning and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992;68:377–395.
Dill-Müller D, Kamradt J, Reichrath J . Expression of retinoic acid receptors (RAR-α,-β,-γ) and retinoid-X receptor-α (RXR-α) in basal cell carcinomas. In: Norman AW, Bouillon R, Thomasset M (eds.). Vitamin D Chemistry, Biology and Clinical Applications of the Steroid Hormone. University of California Printing and Reographics: Riverside, CA, 1997, pp 493–494.
Costa EM, Feldman D . Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology 1987;120:1173–1178.
Wiese RJ, Uhland-Smith A, Ross TK, et al. Up-regulation of vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992;267:20082–20086.
Lehmann B . HaCaT cell line as a model system for vitamin D3 metabolism in human skin. J Invest Dermatol 1997;108:78–82.
Rudolph T, Lehmann B, Pietsch J, et al. Normal human keratinocytes in organotypic culture metabolize vitamin D3 to 1α,25-dihydroxyvitamin D3 . In: Norman AW, Bouillon R, Thomasset M (eds.) Vitamin D Chemistry, Biology and Clinical Applications of the Steroid Hormone. University of California Printing and Reprographics, Riverside, CA, 1997, pp 581–582.
Kamradt J, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cutaneous malignancies. Recent Results Cancer Res 2003;164:259–269.
Reichrath J, Hügel U, Klaus G, et al. Modulation of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in HaCaT keratinocytes. In: Norman AW Bouillon R Thomasset M (eds.). Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application. Walter de Gruyter: Berlin, 1991, pp 445–446.
Krishnan AV, Cramer SD, Bringhurst FR, et al. Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Endocrinology 1995;136:705–712.
Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144–146.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mitschele, T., Diesel, B., Friedrich, M. et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest 84, 693–702 (2004). https://doi.org/10.1038/labinvest.3700096
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/labinvest.3700096
Keywords
- vitamin D
- vitamin D receptor
- basal cell carcinoma
- skin
- vitamin D-25-hydroxylase
- 25-hydroxyvitamin D-1α-hydroxylase
- 1,25-dihydroxyvitamin D-24-hydroxylase
Keywords
This article is cited by
-
Association of DNA methylation of vitamin D metabolic pathway related genes with colorectal cancer risk
Clinical Epigenetics (2023)
-
Exploring vitamin D metabolism and function in cancer
Experimental & Molecular Medicine (2018)
-
Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook
Reviews in Endocrine and Metabolic Disorders (2016)
-
1α, 25-Dihydroxyvitamin D3 and the vitamin D receptor regulates ΔNp63α levels and keratinocyte proliferation
Cell Death & Disease (2015)
-
Non-linear fluorescence lifetime imaging of biological tissues
Analytical and Bioanalytical Chemistry (2011)